Search Medical Condition
Please enter condition
Please choose location from dropdown

North Sydney, Australia Clinical Trials

A listing of North Sydney, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (523) clinical trials

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

This Phase II study is designed to evaluate the safety and efficacy of IMCgp100 compared with Investigator's Choice (dacarbazine, ipilimumab or pembrolizumab) in HLA-A*0201 positive adult patients with advanced UM treated in the first line setting with no prior systemic or liver-directed chemo-, radio- or immune-therapy administered in the advanced ...

Phase

0.91 miles

Learn More »

The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in subjects with unresectable or metastatic melanoma.

Phase

0.91 miles

Learn More »

Neoadjuvant Dabrafenib Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

The new drug options for advanced melanoma include oncogene-targeted therapy (such as dabrafenib, trametinib and vemurafenib) and immune checkpoint blockade (such as pembrolizumab, nivolumab and ipilimumab). These drugs have shown remarkable efficacy and have regulatory approval for metastatic disease. However, most patients with advanced disease eventually progress. It is unknown ...

Phase

0.91 miles

Learn More »

Use of Hair to Diagnose Breast Cancer

The test has the potential to improve the diagnostic (and consequently therapeutic) paradigm for breast cancer. Women attending a radiology clinic in the Mater Hospital, Sydney, for a mammogram will be invited to participate in the study. A few hairs will be cut from their head or pubic region, put ...

Phase

1.04 miles

Learn More »

Osteonecrosis of the Hip and Bisphosphonate Treatment

Osteonecrosis (ON) of the hip is an important cause of musculoskeletal disability and finding therapeutic solutions has proven challenging. Patients who are affected with ON are often relatively young, usually in the third to sixth decade of life. ON of the hip is an increasingly common cause of musculoskeletal disability. ...

Phase

1.04 miles

Learn More »

Randomized Embedded Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Patients with pneumonia who are being treated in an ICU will receive many different treatments, as many as 20 or 30, that act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known ...

Phase

1.04 miles

Learn More »

A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma

The purpose of this study is to determine whether the combination of nivolumab and ipilimumab is safe and effective for delaying or preventing recurrence of cancer in patients who have experienced the partial or entire removal of a kidney

Phase

1.04 miles

Learn More »

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

MDS is an insidious and largely incurable haematological malignancy that increasingly impacts on the well-being of our ageing population, and one for which there has been no significant therapeutic advance since the introduction of injectable AZA (Vidaza) over a decade ago. Furthermore, the basis for the effectiveness of Vidaza or ...

Phase

1.04 miles

Learn More »

Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene

Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption. Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide (60 mg/m2 p.o.) and daily procarbazine (PCB, 50 mg p.o. if BSA < 1.7; ...

Phase

1.04 miles

Learn More »

Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)

Background: Cardiac Resynchronization Therapy (CRT) is an established treatment in heart failure (HF) patients with ventricular dyssynchrony who remain in sinus rhythm. Available clinical data has shown inferior outcomes of CRT in HF patients with co-existent atrial fibrillation (AF), who comprise up to 27% of HF patients, and are over-represented ...

Phase N/A

1.04 miles

Learn More »